Bill and Melin­da Gates Foun­da­tion backs lit­tle-known biotech go­ing af­ter Pfiz­er, Mer­ck on pneu­mo­coc­cal vac­cine

4 years ago
Financing

Amid an al­ready slow roll­out, Bio­gen's Aduhelm could soon face price com­pe­ti­tion — re­port

4 years ago
FDA+

EQT Group ac­quires VC firm in $500M+ deal; Sanofi se­lects IPO lead­ers for 2022 API spin­out — re­port

4 years ago
News Briefing

Opin­ion: The drug pric­ing deal is­n't re­al­ly a vic­to­ry for Dems, or a loss for PhRMA. But it could be a har­bin­ger of ...

4 years ago
Pharma
FDA+

Genen­tech teams with lit­tle Novome on IBD re­search, look­ing to col­o­nized bac­te­ria af­ter a se­vere set­back

4 years ago
Deals

The renowned drug hunter, the Wash­ing­ton in­sid­er, the MIT strate­gist: How did one low-pro­file biotech en­list a dream ...

4 years ago
Bioregnum
Cell/Gene Tx

On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

4 years ago
R&D
Cell/Gene Tx

Lig­and to split in half, spin­ning Om­niAb plat­form in­to its own com­pa­ny

4 years ago
Discovery

Ok­la­homa over­turns his­toric opi­oid de­ci­sion against J&J, wip­ing out $465M fine

4 years ago
Pharma

Mod­er­na and NIH can't agree on who in­vent­ed the life­sav­ing Covid-19 vac­cine, and their feud is now pub­lic — re­port

4 years ago
Coronavirus

The very slow roll of Bio­gen's Aduhelm: Neu­rol­o­gists weigh in on pa­tients, prac­tices and pay­ments amid on­go­ing me­dia ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: J&J qui­et­ly launch­es a new 'World of Well' cor­po­rate cam­paign; Genen­tech spon­sors orig­i­nal song ...

4 years ago
Pharma
Marketing

Move over KOLs, there’s a new in­flu­encer in town. Meet the dig­i­tal opin­ion lead­ers tak­ing over on­line

4 years ago
Pharma
Marketing

Q&A: From Aber­crom­bie to GSK, cus­tomer ex­pe­ri­ence ex­pert Andy Ken­nemer on his fash­ion-for­ward leap to phar­ma

4 years ago
Pharma
Marketing

Ac­cel­er­at­ed ap­provals un­der fire again as piv­otal tri­als typ­i­cal­ly take about as long as con­fir­ma­to­ry tri­als, ...

4 years ago
Pharma
FDA+

Covid-19 roundup: As­traZeneca launch­es new virus R&D di­vi­sion; US buys more of Mer­ck­'s an­tivi­ral pill

4 years ago
Coronavirus

Pfiz­er wa­gers $1.2B on Bio­haven's lead mi­graine drug — and picks up a next-gen can­di­date — as mar­ket­ing wars heat ...

4 years ago
Deals

J&J tries to back out of nanopar­ti­cle li­cense agree­ment — but Alk­er­mes says 'not so fast'

4 years ago
Deals

Com­pass Path­ways' Phase IIb psilo­cy­bin tri­al shows re­duced de­pres­sion symp­toms

4 years ago
News Briefing

Chi­na's Zai Lab spins 2 more li­cens­ing deals, in­clud­ing a sud­den dive in­to neu­ro­science

4 years ago
Deals
China

Im­mat­ics un­veils promis­ing, ear­ly-stage da­ta for a top con­tender in the race to de­vel­op TCRs. Now it has to live up ...

4 years ago
R&D
Cell/Gene Tx

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves ...

4 years ago
Financing

No­var­tis wash­es its hands of an­oth­er bis­pe­cif­ic at the cen­ter of $2.5B Xen­cor deal

4 years ago
Deals
R&D

Feng Zhang’s qui­et spin­out snares $215M in a race for the next big CRISPR com­pa­ny

4 years ago
Financing
Cell/Gene Tx
First page Previous page 616617618619620621622 Next page Last page
A service from the Financial Times